ALDEI.PA stock most active intraday at €0.03 on 17 Feb 2026: volume spike signals short-term interest

We saw ALDEI.PA stock trade at €0.03 intraday on 17 Feb 2026 after a volume surge of 13,014,939 shares, more than double its average. The spike pushed the session range to €0.02–€0.03, attracting attention on EURONEXT for short-term traders. We cover why liquidity moved, how the biotech’s fundamentals and clinical pipeline link to price action, and what that means for traders and longer-term investors.

ALDEI.PA stock intraday price action and volume

ALDEI.PA stock opened at €0.02 and hit a day high of €0.03 and low of €0.02 on EURONEXT during intraday trading. Volume for the session reached 13,014,939 shares, a relative volume of 2.17, indicating this was among the most active European biotech names today. The jump above the 50-day average of €0.02 shows short-term momentum but keeps the price far below the 200-day average of €0.11.

ALDEI.PA stock liquidity and trading metrics

Liquidity is the immediate story: average volume is 5,992,347, so today’s trades doubled normal flow and tightened spreads. Market cap sits at €1,134,989.00 with 42,829,773 shares outstanding, creating a micro-cap profile that often amplifies intraday moves. Traders should note wide intraday swings and low absolute price, which increase slippage and execution risk.

ALDEI.PA stock fundamentals and valuation

Deinove SA reports EPS of -0.24 and a negative PE of -0.11, reflecting losses typical in small biotech. Key ratios: price/sales 3.09, current ratio 1.36, and cash per share €0.13, which shows limited liquidity cushion. We compare this with the Healthcare sector average PE of 31.07, underlining how ALDEI.PA stock is valued very differently due to its early-stage pipeline and small market cap.

ALDEI.PA stock clinical progress, partnerships and news

Product and partner milestones drive valuation for Deinove SA; lead program DNV3837 is in Phase II for C. difficile and partnerships include bioME9rieux and Institut Pasteur. Recent company updates and press releases can move sentiment quickly for ALDEI.PA stock; see the company site for filings and news. Deinove news and Deinove website provide primary disclosures.

ALDEI.PA stock technicals, Meyka grade and analyst view

Technically, ALDEI.PA stock sits above its 50-day average €0.02 but well below its 200-day €0.11, a common pattern in stocks that have seen structural declines. Meyka AI rates ALDEI.PA with a score of 64.81 out of 100 (Grade B, HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. The rating is informational and not investment advice.

ALDEI.PA stock risks and short-term catalysts

Primary risks are clinical trial setbacks, cash burn, and low float volatility; enterprise value is €3,613,989.00, highlighting leverage relative to market cap. Short-term catalysts include Phase II data releases, partnership announcements, or funding rounds, any of which could trigger renewed volume. We see trading as speculative and suitable for risk-tolerant investors only.

Final Thoughts

Key takeaway: ALDEI.PA stock is trading €0.03 intraday on 17 Feb 2026 after a heavy volume spike, signalling short-term trader interest but leaving fundamentals unchanged. Meyka AI’s forecast model projects €0.05 in 12 months, implying an 88.68% upside from today’s €0.0265, while a conservative price target of €0.04 implies 50.94% upside and a downside reference at €0.02 implies -24.63% risk. Meyka AI’s projections are model-based and not guarantees. We recommend monitoring upcoming clinical readouts and cash runway, and treating intraday flows as high volatility trades. For investors focused on fundamentals, track revenue per share €0.01, EPS -0.24, cash per share €0.13, and any financing that would dilute existing holders. Use tight risk controls if trading the intraday momentum and expect fast moves given the small market cap and elevated relative volume.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.